nodes	percent_of_prediction	percent_of_DWPC	metapath
Dipyridamole—SLC29A1—Gemcitabine—urinary bladder cancer	0.149	0.247	CbGbCtD
Dipyridamole—SLC29A1—Fluorouracil—urinary bladder cancer	0.127	0.212	CbGbCtD
Dipyridamole—ABCC5—Fluorouracil—urinary bladder cancer	0.0974	0.162	CbGbCtD
Dipyridamole—ABCC5—Cisplatin—urinary bladder cancer	0.0827	0.137	CbGbCtD
Dipyridamole—ABCC4—Fluorouracil—urinary bladder cancer	0.0468	0.0777	CbGbCtD
Dipyridamole—ABCB1—Mitomycin—urinary bladder cancer	0.0368	0.0612	CbGbCtD
Dipyridamole—ABCC4—Methotrexate—urinary bladder cancer	0.0258	0.0429	CbGbCtD
Dipyridamole—PDE5A—clitoris—urinary bladder cancer	0.02	0.145	CbGeAlD
Dipyridamole—ABCB1—Gemcitabine—urinary bladder cancer	0.0106	0.0176	CbGbCtD
Dipyridamole—ABCB1—Cisplatin—urinary bladder cancer	0.0077	0.0128	CbGbCtD
Dipyridamole—ABCB1—Etoposide—urinary bladder cancer	0.00757	0.0126	CbGbCtD
Dipyridamole—PDE5A—penis—urinary bladder cancer	0.00566	0.041	CbGeAlD
Dipyridamole—PDE3A—penis—urinary bladder cancer	0.00551	0.0398	CbGeAlD
Dipyridamole—ABCB1—Doxorubicin—urinary bladder cancer	0.00516	0.00858	CbGbCtD
Dipyridamole—ABCB1—Methotrexate—urinary bladder cancer	0.005	0.00831	CbGbCtD
Dipyridamole—PDE1C—prostate gland—urinary bladder cancer	0.00446	0.0323	CbGeAlD
Dipyridamole—PRUNE—prostate gland—urinary bladder cancer	0.00402	0.0291	CbGeAlD
Dipyridamole—PDE6D—prostate gland—urinary bladder cancer	0.00388	0.0281	CbGeAlD
Dipyridamole—PDE6B—prostate gland—urinary bladder cancer	0.00382	0.0277	CbGeAlD
Dipyridamole—PDE11A—prostate gland—urinary bladder cancer	0.00355	0.0257	CbGeAlD
Dipyridamole—PRUNE—Podofilox—Etoposide—urinary bladder cancer	0.00354	1	CbGdCrCtD
Dipyridamole—PDE7B—prostate gland—urinary bladder cancer	0.00277	0.02	CbGeAlD
Dipyridamole—PDE11A—epithelium—urinary bladder cancer	0.00261	0.0189	CbGeAlD
Dipyridamole—PDE2A—prostate gland—urinary bladder cancer	0.00231	0.0167	CbGeAlD
Dipyridamole—PDE10A—prostate gland—urinary bladder cancer	0.00231	0.0167	CbGeAlD
Dipyridamole—PDE1B—prostate gland—urinary bladder cancer	0.00229	0.0166	CbGeAlD
Dipyridamole—PDE8B—prostate gland—urinary bladder cancer	0.0022	0.016	CbGeAlD
Dipyridamole—PDE7A—renal system—urinary bladder cancer	0.00216	0.0156	CbGeAlD
Dipyridamole—PDE3B—prostate gland—urinary bladder cancer	0.00215	0.0156	CbGeAlD
Dipyridamole—PDE6D—female reproductive system—urinary bladder cancer	0.00212	0.0153	CbGeAlD
Dipyridamole—PDE8A—prostate gland—urinary bladder cancer	0.00198	0.0143	CbGeAlD
Dipyridamole—PDE2A—seminal vesicle—urinary bladder cancer	0.00195	0.0141	CbGeAlD
Dipyridamole—PDE1A—prostate gland—urinary bladder cancer	0.00192	0.0139	CbGeAlD
Dipyridamole—PDE6D—vagina—urinary bladder cancer	0.00192	0.0139	CbGeAlD
Dipyridamole—PDE6B—vagina—urinary bladder cancer	0.00189	0.0137	CbGeAlD
Dipyridamole—PDE7A—female reproductive system—urinary bladder cancer	0.00173	0.0125	CbGeAlD
Dipyridamole—PDE8A—seminal vesicle—urinary bladder cancer	0.00168	0.0121	CbGeAlD
Dipyridamole—ADA—prostate gland—urinary bladder cancer	0.00163	0.0118	CbGeAlD
Dipyridamole—PDE4A—prostate gland—urinary bladder cancer	0.00159	0.0115	CbGeAlD
Dipyridamole—PDE2A—urethra—urinary bladder cancer	0.00155	0.0112	CbGeAlD
Dipyridamole—PDE1C—lymph node—urinary bladder cancer	0.00142	0.0103	CbGeAlD
Dipyridamole—PDE8A—smooth muscle tissue—urinary bladder cancer	0.0014	0.0102	CbGeAlD
Dipyridamole—PDE1A—smooth muscle tissue—urinary bladder cancer	0.00136	0.00983	CbGeAlD
Dipyridamole—PDE5A—prostate gland—urinary bladder cancer	0.00135	0.00978	CbGeAlD
Dipyridamole—PDE8A—urethra—urinary bladder cancer	0.00133	0.00961	CbGeAlD
Dipyridamole—PDE3A—prostate gland—urinary bladder cancer	0.00132	0.00952	CbGeAlD
Dipyridamole—PDE1A—renal system—urinary bladder cancer	0.00131	0.00947	CbGeAlD
Dipyridamole—PRUNE—lymph node—urinary bladder cancer	0.00128	0.0093	CbGeAlD
Dipyridamole—PDE2A—female reproductive system—urinary bladder cancer	0.00126	0.00913	CbGeAlD
Dipyridamole—PDE1B—female reproductive system—urinary bladder cancer	0.00125	0.00905	CbGeAlD
Dipyridamole—PDE6D—lymph node—urinary bladder cancer	0.00124	0.00898	CbGeAlD
Dipyridamole—ABCC5—prostate gland—urinary bladder cancer	0.00124	0.00895	CbGeAlD
Dipyridamole—PDE8B—female reproductive system—urinary bladder cancer	0.0012	0.00871	CbGeAlD
Dipyridamole—PDE2A—vagina—urinary bladder cancer	0.00114	0.00826	CbGeAlD
Dipyridamole—SLC29A1—prostate gland—urinary bladder cancer	0.00114	0.00822	CbGeAlD
Dipyridamole—ADA—renal system—urinary bladder cancer	0.00111	0.00805	CbGeAlD
Dipyridamole—PDE6G—lymph node—urinary bladder cancer	0.00109	0.0079	CbGeAlD
Dipyridamole—PDE8B—vagina—urinary bladder cancer	0.00109	0.00788	CbGeAlD
Dipyridamole—PDE1A—female reproductive system—urinary bladder cancer	0.00105	0.00758	CbGeAlD
Dipyridamole—PDE5A—epithelium—urinary bladder cancer	0.000993	0.00719	CbGeAlD
Dipyridamole—PDE8A—vagina—urinary bladder cancer	0.000979	0.00708	CbGeAlD
Dipyridamole—PDE5A—smooth muscle tissue—urinary bladder cancer	0.000957	0.00693	CbGeAlD
Dipyridamole—PDE3A—smooth muscle tissue—urinary bladder cancer	0.000931	0.00674	CbGeAlD
Dipyridamole—PDE5A—renal system—urinary bladder cancer	0.000921	0.00667	CbGeAlD
Dipyridamole—PDE5A—urethra—urinary bladder cancer	0.000905	0.00655	CbGeAlD
Dipyridamole—ADA—female reproductive system—urinary bladder cancer	0.000891	0.00645	CbGeAlD
Dipyridamole—PDE7B—lymph node—urinary bladder cancer	0.000884	0.0064	CbGeAlD
Dipyridamole—ABCC4—prostate gland—urinary bladder cancer	0.000857	0.0062	CbGeAlD
Dipyridamole—ADA—vagina—urinary bladder cancer	0.000805	0.00583	CbGeAlD
Dipyridamole—SLC29A1—renal system—urinary bladder cancer	0.000774	0.0056	CbGeAlD
Dipyridamole—SLC29A1—urethra—urinary bladder cancer	0.00076	0.0055	CbGeAlD
Dipyridamole—PDE5A—female reproductive system—urinary bladder cancer	0.000738	0.00534	CbGeAlD
Dipyridamole—PDE2A—lymph node—urinary bladder cancer	0.000738	0.00534	CbGeAlD
Dipyridamole—PDE10A—lymph node—urinary bladder cancer	0.000738	0.00534	CbGeAlD
Dipyridamole—PDE1B—lymph node—urinary bladder cancer	0.000731	0.00529	CbGeAlD
Dipyridamole—PDE3A—female reproductive system—urinary bladder cancer	0.000718	0.0052	CbGeAlD
Dipyridamole—PDE8B—lymph node—urinary bladder cancer	0.000704	0.00509	CbGeAlD
Dipyridamole—PDE3B—lymph node—urinary bladder cancer	0.000687	0.00498	CbGeAlD
Dipyridamole—PDE5A—vagina—urinary bladder cancer	0.000667	0.00483	CbGeAlD
Dipyridamole—PDE8A—lymph node—urinary bladder cancer	0.000633	0.00458	CbGeAlD
Dipyridamole—SLC29A1—female reproductive system—urinary bladder cancer	0.00062	0.00448	CbGeAlD
Dipyridamole—PDE1A—lymph node—urinary bladder cancer	0.000613	0.00443	CbGeAlD
Dipyridamole—ABCC5—vagina—urinary bladder cancer	0.00061	0.00442	CbGeAlD
Dipyridamole—ABCC4—renal system—urinary bladder cancer	0.000584	0.00423	CbGeAlD
Dipyridamole—SLC29A1—vagina—urinary bladder cancer	0.00056	0.00406	CbGeAlD
Dipyridamole—ADA—lymph node—urinary bladder cancer	0.000521	0.00377	CbGeAlD
Dipyridamole—PDE4A—lymph node—urinary bladder cancer	0.000508	0.00367	CbGeAlD
Dipyridamole—ABCC4—female reproductive system—urinary bladder cancer	0.000468	0.00339	CbGeAlD
Dipyridamole—PDE5A—lymph node—urinary bladder cancer	0.000432	0.00312	CbGeAlD
Dipyridamole—PDE3A—lymph node—urinary bladder cancer	0.00042	0.00304	CbGeAlD
Dipyridamole—ABCC5—lymph node—urinary bladder cancer	0.000395	0.00286	CbGeAlD
Dipyridamole—SLC29A1—lymph node—urinary bladder cancer	0.000362	0.00262	CbGeAlD
Dipyridamole—ABCB1—prostate gland—urinary bladder cancer	0.000298	0.00216	CbGeAlD
Dipyridamole—ABCC4—lymph node—urinary bladder cancer	0.000274	0.00198	CbGeAlD
Dipyridamole—ABCB1—seminal vesicle—urinary bladder cancer	0.000252	0.00183	CbGeAlD
Dipyridamole—ABCB1—epithelium—urinary bladder cancer	0.000219	0.00159	CbGeAlD
Dipyridamole—ABCB1—renal system—urinary bladder cancer	0.000203	0.00147	CbGeAlD
Dipyridamole—ABCB1—urethra—urinary bladder cancer	0.0002	0.00145	CbGeAlD
Dipyridamole—ABCB1—female reproductive system—urinary bladder cancer	0.000163	0.00118	CbGeAlD
Dipyridamole—Feeling abnormal—Fluorouracil—urinary bladder cancer	0.000159	0.00107	CcSEcCtD
Dipyridamole—Gastrointestinal disorder—Cisplatin—urinary bladder cancer	0.000158	0.00106	CcSEcCtD
Dipyridamole—Hypotension—Etoposide—urinary bladder cancer	0.000157	0.00106	CcSEcCtD
Dipyridamole—Pain—Cisplatin—urinary bladder cancer	0.000157	0.00105	CcSEcCtD
Dipyridamole—Dizziness—Thiotepa—urinary bladder cancer	0.000155	0.00104	CcSEcCtD
Dipyridamole—Urticaria—Fluorouracil—urinary bladder cancer	0.000154	0.00103	CcSEcCtD
Dipyridamole—Dysphagia—Doxorubicin—urinary bladder cancer	0.000153	0.00103	CcSEcCtD
Dipyridamole—Feeling abnormal—Cisplatin—urinary bladder cancer	0.000151	0.00102	CcSEcCtD
Dipyridamole—Paraesthesia—Etoposide—urinary bladder cancer	0.000151	0.00101	CcSEcCtD
Dipyridamole—Dyspnoea—Etoposide—urinary bladder cancer	0.00015	0.00101	CcSEcCtD
Dipyridamole—Somnolence—Etoposide—urinary bladder cancer	0.000149	0.001	CcSEcCtD
Dipyridamole—Angina pectoris—Doxorubicin—urinary bladder cancer	0.000149	0.001	CcSEcCtD
Dipyridamole—Vomiting—Thiotepa—urinary bladder cancer	0.000149	0.001	CcSEcCtD
Dipyridamole—Rash—Thiotepa—urinary bladder cancer	0.000147	0.000992	CcSEcCtD
Dipyridamole—Dermatitis—Thiotepa—urinary bladder cancer	0.000147	0.000991	CcSEcCtD
Dipyridamole—ABCB1—vagina—urinary bladder cancer	0.000147	0.00107	CbGeAlD
Dipyridamole—Headache—Thiotepa—urinary bladder cancer	0.000146	0.000985	CcSEcCtD
Dipyridamole—Gastrointestinal disorder—Etoposide—urinary bladder cancer	0.000145	0.000975	CcSEcCtD
Dipyridamole—Fatigue—Etoposide—urinary bladder cancer	0.000145	0.000974	CcSEcCtD
Dipyridamole—Pain—Etoposide—urinary bladder cancer	0.000144	0.000966	CcSEcCtD
Dipyridamole—Hypersensitivity—Fluorouracil—urinary bladder cancer	0.000142	0.000958	CcSEcCtD
Dipyridamole—Haemoglobin—Methotrexate—urinary bladder cancer	0.000142	0.000957	CcSEcCtD
Dipyridamole—Hepatitis—Methotrexate—urinary bladder cancer	0.000142	0.000952	CcSEcCtD
Dipyridamole—Haemorrhage—Methotrexate—urinary bladder cancer	0.000142	0.000952	CcSEcCtD
Dipyridamole—Asthenia—Gemcitabine—urinary bladder cancer	0.000141	0.000949	CcSEcCtD
Dipyridamole—Pharyngitis—Methotrexate—urinary bladder cancer	0.000141	0.000945	CcSEcCtD
Dipyridamole—Pruritus—Gemcitabine—urinary bladder cancer	0.000139	0.000936	CcSEcCtD
Dipyridamole—Nausea—Thiotepa—urinary bladder cancer	0.000139	0.000934	CcSEcCtD
Dipyridamole—Feeling abnormal—Etoposide—urinary bladder cancer	0.000138	0.000931	CcSEcCtD
Dipyridamole—Gastrointestinal pain—Etoposide—urinary bladder cancer	0.000137	0.000924	CcSEcCtD
Dipyridamole—Pruritus—Fluorouracil—urinary bladder cancer	0.000137	0.00092	CcSEcCtD
Dipyridamole—Hypersensitivity—Cisplatin—urinary bladder cancer	0.000135	0.000908	CcSEcCtD
Dipyridamole—Bradycardia—Epirubicin—urinary bladder cancer	0.000135	0.000907	CcSEcCtD
Dipyridamole—Diarrhoea—Gemcitabine—urinary bladder cancer	0.000135	0.000905	CcSEcCtD
Dipyridamole—Urticaria—Etoposide—urinary bladder cancer	0.000133	0.000897	CcSEcCtD
Dipyridamole—Haemoglobin—Epirubicin—urinary bladder cancer	0.000133	0.000896	CcSEcCtD
Dipyridamole—Rhinitis—Epirubicin—urinary bladder cancer	0.000133	0.000894	CcSEcCtD
Dipyridamole—Abdominal pain—Etoposide—urinary bladder cancer	0.000133	0.000893	CcSEcCtD
Dipyridamole—Haemorrhage—Epirubicin—urinary bladder cancer	0.000133	0.000891	CcSEcCtD
Dipyridamole—Hepatitis—Epirubicin—urinary bladder cancer	0.000133	0.000891	CcSEcCtD
Dipyridamole—Diarrhoea—Fluorouracil—urinary bladder cancer	0.000132	0.00089	CcSEcCtD
Dipyridamole—Tinnitus—Methotrexate—urinary bladder cancer	0.000132	0.000888	CcSEcCtD
Dipyridamole—Hypoaesthesia—Epirubicin—urinary bladder cancer	0.000132	0.000887	CcSEcCtD
Dipyridamole—Asthenia—Cisplatin—urinary bladder cancer	0.000132	0.000885	CcSEcCtD
Dipyridamole—Pharyngitis—Epirubicin—urinary bladder cancer	0.000132	0.000885	CcSEcCtD
Dipyridamole—Cardiac disorder—Methotrexate—urinary bladder cancer	0.000131	0.000884	CcSEcCtD
Dipyridamole—Angiopathy—Methotrexate—urinary bladder cancer	0.000128	0.000864	CcSEcCtD
Dipyridamole—Immune system disorder—Methotrexate—urinary bladder cancer	0.000128	0.00086	CcSEcCtD
Dipyridamole—Dizziness—Fluorouracil—urinary bladder cancer	0.000128	0.00086	CcSEcCtD
Dipyridamole—Mediastinal disorder—Methotrexate—urinary bladder cancer	0.000128	0.000858	CcSEcCtD
Dipyridamole—Chills—Methotrexate—urinary bladder cancer	0.000127	0.000855	CcSEcCtD
Dipyridamole—Diarrhoea—Cisplatin—urinary bladder cancer	0.000125	0.000844	CcSEcCtD
Dipyridamole—Alopecia—Methotrexate—urinary bladder cancer	0.000125	0.000842	CcSEcCtD
Dipyridamole—Vomiting—Gemcitabine—urinary bladder cancer	0.000125	0.000841	CcSEcCtD
Dipyridamole—Bradycardia—Doxorubicin—urinary bladder cancer	0.000125	0.00084	CcSEcCtD
Dipyridamole—Rash—Gemcitabine—urinary bladder cancer	0.000124	0.000834	CcSEcCtD
Dipyridamole—Dermatitis—Gemcitabine—urinary bladder cancer	0.000124	0.000833	CcSEcCtD
Dipyridamole—Hypersensitivity—Etoposide—urinary bladder cancer	0.000124	0.000832	CcSEcCtD
Dipyridamole—Tinnitus—Epirubicin—urinary bladder cancer	0.000124	0.000831	CcSEcCtD
Dipyridamole—Haemoglobin—Doxorubicin—urinary bladder cancer	0.000123	0.000829	CcSEcCtD
Dipyridamole—Headache—Gemcitabine—urinary bladder cancer	0.000123	0.000829	CcSEcCtD
Dipyridamole—Flushing—Epirubicin—urinary bladder cancer	0.000123	0.000827	CcSEcCtD
Dipyridamole—Cardiac disorder—Epirubicin—urinary bladder cancer	0.000123	0.000827	CcSEcCtD
Dipyridamole—Vomiting—Fluorouracil—urinary bladder cancer	0.000123	0.000827	CcSEcCtD
Dipyridamole—Rhinitis—Doxorubicin—urinary bladder cancer	0.000123	0.000827	CcSEcCtD
Dipyridamole—Haemorrhage—Doxorubicin—urinary bladder cancer	0.000123	0.000825	CcSEcCtD
Dipyridamole—Hepatitis—Doxorubicin—urinary bladder cancer	0.000123	0.000825	CcSEcCtD
Dipyridamole—Hypoaesthesia—Doxorubicin—urinary bladder cancer	0.000122	0.000821	CcSEcCtD
Dipyridamole—Rash—Fluorouracil—urinary bladder cancer	0.000122	0.00082	CcSEcCtD
Dipyridamole—Dermatitis—Fluorouracil—urinary bladder cancer	0.000122	0.000819	CcSEcCtD
Dipyridamole—Pharyngitis—Doxorubicin—urinary bladder cancer	0.000122	0.000818	CcSEcCtD
Dipyridamole—Headache—Fluorouracil—urinary bladder cancer	0.000121	0.000815	CcSEcCtD
Dipyridamole—Dysgeusia—Methotrexate—urinary bladder cancer	0.000121	0.000812	CcSEcCtD
Dipyridamole—Asthenia—Etoposide—urinary bladder cancer	0.000121	0.00081	CcSEcCtD
Dipyridamole—Angiopathy—Epirubicin—urinary bladder cancer	0.00012	0.000809	CcSEcCtD
Dipyridamole—Immune system disorder—Epirubicin—urinary bladder cancer	0.00012	0.000805	CcSEcCtD
Dipyridamole—Mediastinal disorder—Epirubicin—urinary bladder cancer	0.000119	0.000803	CcSEcCtD
Dipyridamole—Back pain—Methotrexate—urinary bladder cancer	0.000119	0.000802	CcSEcCtD
Dipyridamole—Chills—Epirubicin—urinary bladder cancer	0.000119	0.0008	CcSEcCtD
Dipyridamole—Pruritus—Etoposide—urinary bladder cancer	0.000119	0.000799	CcSEcCtD
Dipyridamole—Arrhythmia—Epirubicin—urinary bladder cancer	0.000118	0.000796	CcSEcCtD
Dipyridamole—Alopecia—Epirubicin—urinary bladder cancer	0.000117	0.000788	CcSEcCtD
Dipyridamole—Nausea—Gemcitabine—urinary bladder cancer	0.000117	0.000786	CcSEcCtD
Dipyridamole—Vomiting—Cisplatin—urinary bladder cancer	0.000117	0.000784	CcSEcCtD
Dipyridamole—Rash—Cisplatin—urinary bladder cancer	0.000116	0.000777	CcSEcCtD
Dipyridamole—Dermatitis—Cisplatin—urinary bladder cancer	0.000115	0.000777	CcSEcCtD
Dipyridamole—Diarrhoea—Etoposide—urinary bladder cancer	0.000115	0.000773	CcSEcCtD
Dipyridamole—Nausea—Fluorouracil—urinary bladder cancer	0.000115	0.000773	CcSEcCtD
Dipyridamole—Ill-defined disorder—Methotrexate—urinary bladder cancer	0.000114	0.000769	CcSEcCtD
Dipyridamole—Tinnitus—Doxorubicin—urinary bladder cancer	0.000114	0.000769	CcSEcCtD
Dipyridamole—Anaemia—Methotrexate—urinary bladder cancer	0.000114	0.000766	CcSEcCtD
Dipyridamole—Flushing—Doxorubicin—urinary bladder cancer	0.000114	0.000765	CcSEcCtD
Dipyridamole—Cardiac disorder—Doxorubicin—urinary bladder cancer	0.000114	0.000765	CcSEcCtD
Dipyridamole—Flatulence—Epirubicin—urinary bladder cancer	0.000114	0.000765	CcSEcCtD
Dipyridamole—Tension—Epirubicin—urinary bladder cancer	0.000113	0.000761	CcSEcCtD
Dipyridamole—Dysgeusia—Epirubicin—urinary bladder cancer	0.000113	0.00076	CcSEcCtD
Dipyridamole—Nervousness—Epirubicin—urinary bladder cancer	0.000112	0.000754	CcSEcCtD
Dipyridamole—Back pain—Epirubicin—urinary bladder cancer	0.000112	0.00075	CcSEcCtD
Dipyridamole—Angiopathy—Doxorubicin—urinary bladder cancer	0.000111	0.000748	CcSEcCtD
Dipyridamole—Malaise—Methotrexate—urinary bladder cancer	0.000111	0.000748	CcSEcCtD
Dipyridamole—Dizziness—Etoposide—urinary bladder cancer	0.000111	0.000747	CcSEcCtD
Dipyridamole—Muscle spasms—Epirubicin—urinary bladder cancer	0.000111	0.000746	CcSEcCtD
Dipyridamole—Immune system disorder—Doxorubicin—urinary bladder cancer	0.000111	0.000745	CcSEcCtD
Dipyridamole—Vertigo—Methotrexate—urinary bladder cancer	0.000111	0.000745	CcSEcCtD
Dipyridamole—Mediastinal disorder—Doxorubicin—urinary bladder cancer	0.000111	0.000743	CcSEcCtD
Dipyridamole—Chills—Doxorubicin—urinary bladder cancer	0.00011	0.00074	CcSEcCtD
Dipyridamole—Arrhythmia—Doxorubicin—urinary bladder cancer	0.00011	0.000737	CcSEcCtD
Dipyridamole—Nausea—Cisplatin—urinary bladder cancer	0.000109	0.000732	CcSEcCtD
Dipyridamole—Alopecia—Doxorubicin—urinary bladder cancer	0.000108	0.000729	CcSEcCtD
Dipyridamole—Cough—Methotrexate—urinary bladder cancer	0.000108	0.000723	CcSEcCtD
Dipyridamole—Ill-defined disorder—Epirubicin—urinary bladder cancer	0.000107	0.00072	CcSEcCtD
Dipyridamole—Convulsion—Methotrexate—urinary bladder cancer	0.000107	0.000718	CcSEcCtD
Dipyridamole—Vomiting—Etoposide—urinary bladder cancer	0.000107	0.000718	CcSEcCtD
Dipyridamole—Anaemia—Epirubicin—urinary bladder cancer	0.000107	0.000717	CcSEcCtD
Dipyridamole—Rash—Etoposide—urinary bladder cancer	0.000106	0.000712	CcSEcCtD
Dipyridamole—Dermatitis—Etoposide—urinary bladder cancer	0.000106	0.000712	CcSEcCtD
Dipyridamole—Headache—Etoposide—urinary bladder cancer	0.000105	0.000708	CcSEcCtD
Dipyridamole—Flatulence—Doxorubicin—urinary bladder cancer	0.000105	0.000707	CcSEcCtD
Dipyridamole—Chest pain—Methotrexate—urinary bladder cancer	0.000105	0.000706	CcSEcCtD
Dipyridamole—Myalgia—Methotrexate—urinary bladder cancer	0.000105	0.000706	CcSEcCtD
Dipyridamole—Arthralgia—Methotrexate—urinary bladder cancer	0.000105	0.000706	CcSEcCtD
Dipyridamole—Tension—Doxorubicin—urinary bladder cancer	0.000105	0.000704	CcSEcCtD
Dipyridamole—Dysgeusia—Doxorubicin—urinary bladder cancer	0.000105	0.000703	CcSEcCtD
Dipyridamole—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	0.000104	0.000701	CcSEcCtD
Dipyridamole—Malaise—Epirubicin—urinary bladder cancer	0.000104	0.0007	CcSEcCtD
Dipyridamole—Discomfort—Methotrexate—urinary bladder cancer	0.000104	0.000697	CcSEcCtD
Dipyridamole—Nervousness—Doxorubicin—urinary bladder cancer	0.000104	0.000697	CcSEcCtD
Dipyridamole—Vertigo—Epirubicin—urinary bladder cancer	0.000104	0.000697	CcSEcCtD
Dipyridamole—Syncope—Epirubicin—urinary bladder cancer	0.000103	0.000696	CcSEcCtD
Dipyridamole—Back pain—Doxorubicin—urinary bladder cancer	0.000103	0.000694	CcSEcCtD
Dipyridamole—Muscle spasms—Doxorubicin—urinary bladder cancer	0.000103	0.00069	CcSEcCtD
Dipyridamole—Palpitations—Epirubicin—urinary bladder cancer	0.000102	0.000686	CcSEcCtD
Dipyridamole—Loss of consciousness—Epirubicin—urinary bladder cancer	0.000101	0.000682	CcSEcCtD
Dipyridamole—Cough—Epirubicin—urinary bladder cancer	0.000101	0.000677	CcSEcCtD
Dipyridamole—Anaphylactic shock—Methotrexate—urinary bladder cancer	0.000101	0.000677	CcSEcCtD
Dipyridamole—Convulsion—Epirubicin—urinary bladder cancer	9.99e-05	0.000672	CcSEcCtD
Dipyridamole—Nausea—Etoposide—urinary bladder cancer	9.98e-05	0.000671	CcSEcCtD
Dipyridamole—Hypertension—Epirubicin—urinary bladder cancer	9.96e-05	0.00067	CcSEcCtD
Dipyridamole—Ill-defined disorder—Doxorubicin—urinary bladder cancer	9.9e-05	0.000666	CcSEcCtD
Dipyridamole—Nervous system disorder—Methotrexate—urinary bladder cancer	9.87e-05	0.000664	CcSEcCtD
Dipyridamole—Anaemia—Doxorubicin—urinary bladder cancer	9.87e-05	0.000664	CcSEcCtD
Dipyridamole—Thrombocytopenia—Methotrexate—urinary bladder cancer	9.85e-05	0.000662	CcSEcCtD
Dipyridamole—Chest pain—Epirubicin—urinary bladder cancer	9.82e-05	0.000661	CcSEcCtD
Dipyridamole—Arthralgia—Epirubicin—urinary bladder cancer	9.82e-05	0.000661	CcSEcCtD
Dipyridamole—Myalgia—Epirubicin—urinary bladder cancer	9.82e-05	0.000661	CcSEcCtD
Dipyridamole—Anxiety—Epirubicin—urinary bladder cancer	9.79e-05	0.000658	CcSEcCtD
Dipyridamole—Skin disorder—Methotrexate—urinary bladder cancer	9.77e-05	0.000657	CcSEcCtD
Dipyridamole—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	9.75e-05	0.000656	CcSEcCtD
Dipyridamole—Hyperhidrosis—Methotrexate—urinary bladder cancer	9.73e-05	0.000654	CcSEcCtD
Dipyridamole—Discomfort—Epirubicin—urinary bladder cancer	9.7e-05	0.000653	CcSEcCtD
Dipyridamole—Malaise—Doxorubicin—urinary bladder cancer	9.63e-05	0.000647	CcSEcCtD
Dipyridamole—Dry mouth—Epirubicin—urinary bladder cancer	9.6e-05	0.000646	CcSEcCtD
Dipyridamole—Vertigo—Doxorubicin—urinary bladder cancer	9.59e-05	0.000645	CcSEcCtD
Dipyridamole—Syncope—Doxorubicin—urinary bladder cancer	9.57e-05	0.000644	CcSEcCtD
Dipyridamole—ABCB1—lymph node—urinary bladder cancer	9.53e-05	0.000689	CbGeAlD
Dipyridamole—Palpitations—Doxorubicin—urinary bladder cancer	9.43e-05	0.000634	CcSEcCtD
Dipyridamole—Anaphylactic shock—Epirubicin—urinary bladder cancer	9.41e-05	0.000633	CcSEcCtD
Dipyridamole—Oedema—Epirubicin—urinary bladder cancer	9.41e-05	0.000633	CcSEcCtD
Dipyridamole—Hypotension—Methotrexate—urinary bladder cancer	9.4e-05	0.000632	CcSEcCtD
Dipyridamole—Loss of consciousness—Doxorubicin—urinary bladder cancer	9.38e-05	0.000631	CcSEcCtD
Dipyridamole—Cough—Doxorubicin—urinary bladder cancer	9.31e-05	0.000626	CcSEcCtD
Dipyridamole—Shock—Epirubicin—urinary bladder cancer	9.26e-05	0.000623	CcSEcCtD
Dipyridamole—Convulsion—Doxorubicin—urinary bladder cancer	9.25e-05	0.000622	CcSEcCtD
Dipyridamole—Nervous system disorder—Epirubicin—urinary bladder cancer	9.23e-05	0.000621	CcSEcCtD
Dipyridamole—Thrombocytopenia—Epirubicin—urinary bladder cancer	9.22e-05	0.00062	CcSEcCtD
Dipyridamole—Hypertension—Doxorubicin—urinary bladder cancer	9.22e-05	0.00062	CcSEcCtD
Dipyridamole—Tachycardia—Epirubicin—urinary bladder cancer	9.19e-05	0.000618	CcSEcCtD
Dipyridamole—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	9.17e-05	0.000616	CcSEcCtD
Dipyridamole—Skin disorder—Epirubicin—urinary bladder cancer	9.14e-05	0.000615	CcSEcCtD
Dipyridamole—Hyperhidrosis—Epirubicin—urinary bladder cancer	9.1e-05	0.000612	CcSEcCtD
Dipyridamole—Myalgia—Doxorubicin—urinary bladder cancer	9.09e-05	0.000611	CcSEcCtD
Dipyridamole—Arthralgia—Doxorubicin—urinary bladder cancer	9.09e-05	0.000611	CcSEcCtD
Dipyridamole—Chest pain—Doxorubicin—urinary bladder cancer	9.09e-05	0.000611	CcSEcCtD
Dipyridamole—Anxiety—Doxorubicin—urinary bladder cancer	9.06e-05	0.000609	CcSEcCtD
Dipyridamole—Paraesthesia—Methotrexate—urinary bladder cancer	9.03e-05	0.000608	CcSEcCtD
Dipyridamole—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	9.02e-05	0.000607	CcSEcCtD
Dipyridamole—Discomfort—Doxorubicin—urinary bladder cancer	8.98e-05	0.000604	CcSEcCtD
Dipyridamole—Dyspnoea—Methotrexate—urinary bladder cancer	8.97e-05	0.000603	CcSEcCtD
Dipyridamole—Somnolence—Methotrexate—urinary bladder cancer	8.94e-05	0.000602	CcSEcCtD
Dipyridamole—Dry mouth—Doxorubicin—urinary bladder cancer	8.89e-05	0.000598	CcSEcCtD
Dipyridamole—Dyspepsia—Methotrexate—urinary bladder cancer	8.86e-05	0.000596	CcSEcCtD
Dipyridamole—Hypotension—Epirubicin—urinary bladder cancer	8.8e-05	0.000592	CcSEcCtD
Dipyridamole—Oedema—Doxorubicin—urinary bladder cancer	8.71e-05	0.000586	CcSEcCtD
Dipyridamole—Anaphylactic shock—Doxorubicin—urinary bladder cancer	8.71e-05	0.000586	CcSEcCtD
Dipyridamole—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	8.69e-05	0.000584	CcSEcCtD
Dipyridamole—Fatigue—Methotrexate—urinary bladder cancer	8.67e-05	0.000583	CcSEcCtD
Dipyridamole—Pain—Methotrexate—urinary bladder cancer	8.6e-05	0.000579	CcSEcCtD
Dipyridamole—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	8.58e-05	0.000577	CcSEcCtD
Dipyridamole—Shock—Doxorubicin—urinary bladder cancer	8.57e-05	0.000576	CcSEcCtD
Dipyridamole—Nervous system disorder—Doxorubicin—urinary bladder cancer	8.54e-05	0.000575	CcSEcCtD
Dipyridamole—Thrombocytopenia—Doxorubicin—urinary bladder cancer	8.53e-05	0.000574	CcSEcCtD
Dipyridamole—Tachycardia—Doxorubicin—urinary bladder cancer	8.5e-05	0.000572	CcSEcCtD
Dipyridamole—Skin disorder—Doxorubicin—urinary bladder cancer	8.46e-05	0.000569	CcSEcCtD
Dipyridamole—Paraesthesia—Epirubicin—urinary bladder cancer	8.45e-05	0.000569	CcSEcCtD
Dipyridamole—Hyperhidrosis—Doxorubicin—urinary bladder cancer	8.42e-05	0.000566	CcSEcCtD
Dipyridamole—Dyspnoea—Epirubicin—urinary bladder cancer	8.39e-05	0.000565	CcSEcCtD
Dipyridamole—Somnolence—Epirubicin—urinary bladder cancer	8.37e-05	0.000563	CcSEcCtD
Dipyridamole—Feeling abnormal—Methotrexate—urinary bladder cancer	8.29e-05	0.000558	CcSEcCtD
Dipyridamole—Dyspepsia—Epirubicin—urinary bladder cancer	8.29e-05	0.000557	CcSEcCtD
Dipyridamole—Gastrointestinal pain—Methotrexate—urinary bladder cancer	8.23e-05	0.000553	CcSEcCtD
Dipyridamole—Hypotension—Doxorubicin—urinary bladder cancer	8.14e-05	0.000547	CcSEcCtD
Dipyridamole—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	8.13e-05	0.000547	CcSEcCtD
Dipyridamole—Fatigue—Epirubicin—urinary bladder cancer	8.12e-05	0.000546	CcSEcCtD
Dipyridamole—Pain—Epirubicin—urinary bladder cancer	8.05e-05	0.000541	CcSEcCtD
Dipyridamole—Urticaria—Methotrexate—urinary bladder cancer	7.99e-05	0.000538	CcSEcCtD
Dipyridamole—Abdominal pain—Methotrexate—urinary bladder cancer	7.95e-05	0.000535	CcSEcCtD
Dipyridamole—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	7.94e-05	0.000534	CcSEcCtD
Dipyridamole—Paraesthesia—Doxorubicin—urinary bladder cancer	7.82e-05	0.000526	CcSEcCtD
Dipyridamole—Dyspnoea—Doxorubicin—urinary bladder cancer	7.77e-05	0.000522	CcSEcCtD
Dipyridamole—Feeling abnormal—Epirubicin—urinary bladder cancer	7.76e-05	0.000522	CcSEcCtD
Dipyridamole—Somnolence—Doxorubicin—urinary bladder cancer	7.74e-05	0.000521	CcSEcCtD
Dipyridamole—Gastrointestinal pain—Epirubicin—urinary bladder cancer	7.7e-05	0.000518	CcSEcCtD
Dipyridamole—Dyspepsia—Doxorubicin—urinary bladder cancer	7.67e-05	0.000516	CcSEcCtD
Dipyridamole—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	7.52e-05	0.000506	CcSEcCtD
Dipyridamole—Fatigue—Doxorubicin—urinary bladder cancer	7.51e-05	0.000505	CcSEcCtD
Dipyridamole—Urticaria—Epirubicin—urinary bladder cancer	7.48e-05	0.000503	CcSEcCtD
Dipyridamole—Pain—Doxorubicin—urinary bladder cancer	7.45e-05	0.000501	CcSEcCtD
Dipyridamole—Abdominal pain—Epirubicin—urinary bladder cancer	7.44e-05	0.000501	CcSEcCtD
Dipyridamole—Hypersensitivity—Methotrexate—urinary bladder cancer	7.41e-05	0.000499	CcSEcCtD
Dipyridamole—Asthenia—Methotrexate—urinary bladder cancer	7.22e-05	0.000485	CcSEcCtD
Dipyridamole—Feeling abnormal—Doxorubicin—urinary bladder cancer	7.18e-05	0.000483	CcSEcCtD
Dipyridamole—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	7.12e-05	0.000479	CcSEcCtD
Dipyridamole—Pruritus—Methotrexate—urinary bladder cancer	7.12e-05	0.000479	CcSEcCtD
Dipyridamole—Hypersensitivity—Epirubicin—urinary bladder cancer	6.94e-05	0.000467	CcSEcCtD
Dipyridamole—Urticaria—Doxorubicin—urinary bladder cancer	6.92e-05	0.000465	CcSEcCtD
Dipyridamole—Abdominal pain—Doxorubicin—urinary bladder cancer	6.89e-05	0.000463	CcSEcCtD
Dipyridamole—Diarrhoea—Methotrexate—urinary bladder cancer	6.88e-05	0.000463	CcSEcCtD
Dipyridamole—Asthenia—Epirubicin—urinary bladder cancer	6.75e-05	0.000454	CcSEcCtD
Dipyridamole—Pruritus—Epirubicin—urinary bladder cancer	6.66e-05	0.000448	CcSEcCtD
Dipyridamole—Dizziness—Methotrexate—urinary bladder cancer	6.65e-05	0.000447	CcSEcCtD
Dipyridamole—Diarrhoea—Epirubicin—urinary bladder cancer	6.44e-05	0.000433	CcSEcCtD
Dipyridamole—Hypersensitivity—Doxorubicin—urinary bladder cancer	6.42e-05	0.000432	CcSEcCtD
Dipyridamole—Vomiting—Methotrexate—urinary bladder cancer	6.4e-05	0.00043	CcSEcCtD
Dipyridamole—Rash—Methotrexate—urinary bladder cancer	6.34e-05	0.000427	CcSEcCtD
Dipyridamole—Dermatitis—Methotrexate—urinary bladder cancer	6.34e-05	0.000426	CcSEcCtD
Dipyridamole—Headache—Methotrexate—urinary bladder cancer	6.3e-05	0.000424	CcSEcCtD
Dipyridamole—Asthenia—Doxorubicin—urinary bladder cancer	6.25e-05	0.00042	CcSEcCtD
Dipyridamole—Dizziness—Epirubicin—urinary bladder cancer	6.23e-05	0.000419	CcSEcCtD
Dipyridamole—Pruritus—Doxorubicin—urinary bladder cancer	6.16e-05	0.000415	CcSEcCtD
Dipyridamole—Vomiting—Epirubicin—urinary bladder cancer	5.99e-05	0.000403	CcSEcCtD
Dipyridamole—Nausea—Methotrexate—urinary bladder cancer	5.98e-05	0.000402	CcSEcCtD
Dipyridamole—Diarrhoea—Doxorubicin—urinary bladder cancer	5.96e-05	0.000401	CcSEcCtD
Dipyridamole—Rash—Epirubicin—urinary bladder cancer	5.94e-05	0.000399	CcSEcCtD
Dipyridamole—Dermatitis—Epirubicin—urinary bladder cancer	5.93e-05	0.000399	CcSEcCtD
Dipyridamole—Headache—Epirubicin—urinary bladder cancer	5.9e-05	0.000397	CcSEcCtD
Dipyridamole—Dizziness—Doxorubicin—urinary bladder cancer	5.76e-05	0.000387	CcSEcCtD
Dipyridamole—Nausea—Epirubicin—urinary bladder cancer	5.59e-05	0.000376	CcSEcCtD
Dipyridamole—Vomiting—Doxorubicin—urinary bladder cancer	5.54e-05	0.000373	CcSEcCtD
Dipyridamole—Rash—Doxorubicin—urinary bladder cancer	5.49e-05	0.000369	CcSEcCtD
Dipyridamole—Dermatitis—Doxorubicin—urinary bladder cancer	5.49e-05	0.000369	CcSEcCtD
Dipyridamole—Headache—Doxorubicin—urinary bladder cancer	5.46e-05	0.000367	CcSEcCtD
Dipyridamole—Nausea—Doxorubicin—urinary bladder cancer	5.17e-05	0.000348	CcSEcCtD
Dipyridamole—ABCC5—Disease—RHOA—urinary bladder cancer	1.55e-05	0.000144	CbGpPWpGaD
Dipyridamole—PDE1A—Disease—RHOA—urinary bladder cancer	1.55e-05	0.000144	CbGpPWpGaD
Dipyridamole—PDE10A—Signaling Pathways—CDKN1A—urinary bladder cancer	1.55e-05	0.000144	CbGpPWpGaD
Dipyridamole—PDE10A—Signaling Pathways—PTEN—urinary bladder cancer	1.55e-05	0.000144	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling by GPCR—IL2—urinary bladder cancer	1.55e-05	0.000143	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—FGFR3—urinary bladder cancer	1.54e-05	0.000143	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—TERT—urinary bladder cancer	1.54e-05	0.000143	CbGpPWpGaD
Dipyridamole—PDE1C—Signaling Pathways—EP300—urinary bladder cancer	1.54e-05	0.000143	CbGpPWpGaD
Dipyridamole—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1A—urinary bladder cancer	1.52e-05	0.000141	CbGpPWpGaD
Dipyridamole—PDE7B—Signaling Pathways—EGFR—urinary bladder cancer	1.52e-05	0.000141	CbGpPWpGaD
Dipyridamole—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—urinary bladder cancer	1.52e-05	0.000141	CbGpPWpGaD
Dipyridamole—PDE6G—Signaling Pathways—EP300—urinary bladder cancer	1.52e-05	0.000141	CbGpPWpGaD
Dipyridamole—PDE1B—Hemostasis—HRAS—urinary bladder cancer	1.51e-05	0.00014	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—FGFR3—urinary bladder cancer	1.5e-05	0.000139	CbGpPWpGaD
Dipyridamole—PDE1C—Disease—HRAS—urinary bladder cancer	1.5e-05	0.000139	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—ESR1—urinary bladder cancer	1.5e-05	0.000139	CbGpPWpGaD
Dipyridamole—ABCC5—Metabolism—PPARG—urinary bladder cancer	1.5e-05	0.000139	CbGpPWpGaD
Dipyridamole—PDE1C—Signaling Pathways—SRC—urinary bladder cancer	1.5e-05	0.000139	CbGpPWpGaD
Dipyridamole—PDE1A—Innate Immune System—HRAS—urinary bladder cancer	1.49e-05	0.000138	CbGpPWpGaD
Dipyridamole—PDE6G—Disease—HRAS—urinary bladder cancer	1.48e-05	0.000138	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling by GPCR—CXCL8—urinary bladder cancer	1.48e-05	0.000137	CbGpPWpGaD
Dipyridamole—PDE10A—Signaling Pathways—EP300—urinary bladder cancer	1.48e-05	0.000137	CbGpPWpGaD
Dipyridamole—PDE6G—Signaling Pathways—SRC—urinary bladder cancer	1.47e-05	0.000137	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—ESR1—urinary bladder cancer	1.46e-05	0.000135	CbGpPWpGaD
Dipyridamole—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—urinary bladder cancer	1.45e-05	0.000134	CbGpPWpGaD
Dipyridamole—PDE11A—Signaling Pathways—MYC—urinary bladder cancer	1.45e-05	0.000134	CbGpPWpGaD
Dipyridamole—PDE7A—Signaling Pathways—MYC—urinary bladder cancer	1.45e-05	0.000134	CbGpPWpGaD
Dipyridamole—ABCC5—Metabolism—CREBBP—urinary bladder cancer	1.44e-05	0.000134	CbGpPWpGaD
Dipyridamole—ABCC5—Disease—ERBB2—urinary bladder cancer	1.44e-05	0.000134	CbGpPWpGaD
Dipyridamole—PDE1A—Disease—ERBB2—urinary bladder cancer	1.44e-05	0.000134	CbGpPWpGaD
Dipyridamole—PDE10A—Signaling Pathways—SRC—urinary bladder cancer	1.44e-05	0.000133	CbGpPWpGaD
Dipyridamole—PDE7B—Signaling Pathways—KRAS—urinary bladder cancer	1.44e-05	0.000133	CbGpPWpGaD
Dipyridamole—PDE8B—Signaling Pathways—TP53—urinary bladder cancer	1.43e-05	0.000133	CbGpPWpGaD
Dipyridamole—PDE8A—Signaling Pathways—TP53—urinary bladder cancer	1.43e-05	0.000133	CbGpPWpGaD
Dipyridamole—PDE1B—Immune System—ERBB2—urinary bladder cancer	1.42e-05	0.000132	CbGpPWpGaD
Dipyridamole—PDE1B—Disease—RHOA—urinary bladder cancer	1.42e-05	0.000132	CbGpPWpGaD
Dipyridamole—ADA—Metabolism—PTEN—urinary bladder cancer	1.41e-05	0.000131	CbGpPWpGaD
Dipyridamole—PDE11A—Signaling Pathways—EGFR—urinary bladder cancer	1.41e-05	0.000131	CbGpPWpGaD
Dipyridamole—PDE7A—Signaling Pathways—EGFR—urinary bladder cancer	1.41e-05	0.000131	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling by GPCR—IL2—urinary bladder cancer	1.41e-05	0.000131	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—FGFR3—urinary bladder cancer	1.41e-05	0.000131	CbGpPWpGaD
Dipyridamole—PDE1A—Immune System—IL2—urinary bladder cancer	1.41e-05	0.000131	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—TERT—urinary bladder cancer	1.41e-05	0.000131	CbGpPWpGaD
Dipyridamole—ABCB1—Integrated Pancreatic Cancer Pathway—SRC—urinary bladder cancer	1.41e-05	0.000131	CbGpPWpGaD
Dipyridamole—PDE1A—Disease—PTGS2—urinary bladder cancer	1.41e-05	0.000131	CbGpPWpGaD
Dipyridamole—ABCC5—Disease—PTGS2—urinary bladder cancer	1.41e-05	0.000131	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—CREBBP—urinary bladder cancer	1.4e-05	0.00013	CbGpPWpGaD
Dipyridamole—PDE2A—Signaling Pathways—TP53—urinary bladder cancer	1.4e-05	0.00013	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—IGF1—urinary bladder cancer	1.39e-05	0.000129	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling by GPCR—EGFR—urinary bladder cancer	1.38e-05	0.000128	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—ESR1—urinary bladder cancer	1.37e-05	0.000127	CbGpPWpGaD
Dipyridamole—PDE8B—Signaling Pathways—HRAS—urinary bladder cancer	1.37e-05	0.000127	CbGpPWpGaD
Dipyridamole—PDE8A—Signaling Pathways—HRAS—urinary bladder cancer	1.37e-05	0.000127	CbGpPWpGaD
Dipyridamole—PDE1B—Innate Immune System—HRAS—urinary bladder cancer	1.36e-05	0.000126	CbGpPWpGaD
Dipyridamole—ABCC4—Hemostasis—KRAS—urinary bladder cancer	1.35e-05	0.000125	CbGpPWpGaD
Dipyridamole—ADA—Metabolism—EP300—urinary bladder cancer	1.35e-05	0.000125	CbGpPWpGaD
Dipyridamole—PDE1C—Signaling Pathways—MYC—urinary bladder cancer	1.34e-05	0.000124	CbGpPWpGaD
Dipyridamole—PDE11A—Signaling Pathways—KRAS—urinary bladder cancer	1.34e-05	0.000124	CbGpPWpGaD
Dipyridamole—PDE7A—Signaling Pathways—KRAS—urinary bladder cancer	1.34e-05	0.000124	CbGpPWpGaD
Dipyridamole—PDE2A—Signaling Pathways—HRAS—urinary bladder cancer	1.33e-05	0.000124	CbGpPWpGaD
Dipyridamole—PDE1A—Immune System—CDKN1A—urinary bladder cancer	1.33e-05	0.000124	CbGpPWpGaD
Dipyridamole—PDE1A—Immune System—PTEN—urinary bladder cancer	1.33e-05	0.000123	CbGpPWpGaD
Dipyridamole—PDE6G—Signaling Pathways—MYC—urinary bladder cancer	1.32e-05	0.000123	CbGpPWpGaD
Dipyridamole—PDE1B—Disease—ERBB2—urinary bladder cancer	1.32e-05	0.000122	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—CREBBP—urinary bladder cancer	1.31e-05	0.000122	CbGpPWpGaD
Dipyridamole—PDE1C—Signaling Pathways—EGFR—urinary bladder cancer	1.31e-05	0.000122	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling by GPCR—KRAS—urinary bladder cancer	1.3e-05	0.000121	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—IGF1—urinary bladder cancer	1.3e-05	0.000121	CbGpPWpGaD
Dipyridamole—PDE6G—Signaling Pathways—EGFR—urinary bladder cancer	1.29e-05	0.00012	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—FGFR3—urinary bladder cancer	1.29e-05	0.00012	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling by GPCR—EGFR—urinary bladder cancer	1.29e-05	0.00012	CbGpPWpGaD
Dipyridamole—PDE1B—Immune System—IL2—urinary bladder cancer	1.29e-05	0.00012	CbGpPWpGaD
Dipyridamole—PDE10A—Signaling Pathways—MYC—urinary bladder cancer	1.29e-05	0.00012	CbGpPWpGaD
Dipyridamole—PDE1B—Disease—PTGS2—urinary bladder cancer	1.29e-05	0.000119	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—TYMP—urinary bladder cancer	1.29e-05	0.000119	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—CREBBP—urinary bladder cancer	1.28e-05	0.000119	CbGpPWpGaD
Dipyridamole—PDE7B—Signaling Pathways—TP53—urinary bladder cancer	1.28e-05	0.000118	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—RHOA—urinary bladder cancer	1.27e-05	0.000118	CbGpPWpGaD
Dipyridamole—PDE1A—Immune System—EP300—urinary bladder cancer	1.27e-05	0.000118	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—IGF1—urinary bladder cancer	1.26e-05	0.000117	CbGpPWpGaD
Dipyridamole—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—urinary bladder cancer	1.26e-05	0.000117	CbGpPWpGaD
Dipyridamole—PDE10A—Signaling Pathways—EGFR—urinary bladder cancer	1.26e-05	0.000117	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling by GPCR—EGFR—urinary bladder cancer	1.26e-05	0.000117	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—ESR1—urinary bladder cancer	1.25e-05	0.000116	CbGpPWpGaD
Dipyridamole—PDE1C—Signaling Pathways—KRAS—urinary bladder cancer	1.24e-05	0.000115	CbGpPWpGaD
Dipyridamole—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—urinary bladder cancer	1.23e-05	0.000115	CbGpPWpGaD
Dipyridamole—PDE1A—Immune System—SRC—urinary bladder cancer	1.23e-05	0.000114	CbGpPWpGaD
Dipyridamole—PDE1A—Disease—CDKN1A—urinary bladder cancer	1.23e-05	0.000114	CbGpPWpGaD
Dipyridamole—ABCC5—Disease—CDKN1A—urinary bladder cancer	1.23e-05	0.000114	CbGpPWpGaD
Dipyridamole—ABCC5—Disease—PTEN—urinary bladder cancer	1.23e-05	0.000114	CbGpPWpGaD
Dipyridamole—PDE1A—Disease—PTEN—urinary bladder cancer	1.23e-05	0.000114	CbGpPWpGaD
Dipyridamole—PDE6G—Signaling Pathways—KRAS—urinary bladder cancer	1.22e-05	0.000113	CbGpPWpGaD
Dipyridamole—PDE7B—Signaling Pathways—HRAS—urinary bladder cancer	1.22e-05	0.000113	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling by GPCR—KRAS—urinary bladder cancer	1.22e-05	0.000113	CbGpPWpGaD
Dipyridamole—PDE1B—Immune System—CDKN1A—urinary bladder cancer	1.22e-05	0.000113	CbGpPWpGaD
Dipyridamole—PDE1B—Immune System—PTEN—urinary bladder cancer	1.21e-05	0.000113	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—CREBBP—urinary bladder cancer	1.2e-05	0.000112	CbGpPWpGaD
Dipyridamole—ABCC4—Hemostasis—TP53—urinary bladder cancer	1.2e-05	0.000111	CbGpPWpGaD
Dipyridamole—PDE10A—Signaling Pathways—KRAS—urinary bladder cancer	1.19e-05	0.00011	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—RHOA—urinary bladder cancer	1.19e-05	0.00011	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—IGF1—urinary bladder cancer	1.19e-05	0.00011	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling by GPCR—KRAS—urinary bladder cancer	1.19e-05	0.00011	CbGpPWpGaD
Dipyridamole—PDE7A—Signaling Pathways—TP53—urinary bladder cancer	1.19e-05	0.00011	CbGpPWpGaD
Dipyridamole—PDE11A—Signaling Pathways—TP53—urinary bladder cancer	1.19e-05	0.00011	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling by GPCR—EGFR—urinary bladder cancer	1.18e-05	0.00011	CbGpPWpGaD
Dipyridamole—ABCC5—Metabolism—PTGS2—urinary bladder cancer	1.18e-05	0.000109	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—ERBB2—urinary bladder cancer	1.18e-05	0.000109	CbGpPWpGaD
Dipyridamole—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—urinary bladder cancer	1.17e-05	0.000109	CbGpPWpGaD
Dipyridamole—PDE1A—Disease—EP300—urinary bladder cancer	1.17e-05	0.000109	CbGpPWpGaD
Dipyridamole—ABCC5—Disease—EP300—urinary bladder cancer	1.17e-05	0.000109	CbGpPWpGaD
Dipyridamole—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—urinary bladder cancer	1.17e-05	0.000108	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—NAT2—urinary bladder cancer	1.16e-05	0.000108	CbGpPWpGaD
Dipyridamole—PDE1B—Immune System—EP300—urinary bladder cancer	1.16e-05	0.000108	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—RHOA—urinary bladder cancer	1.16e-05	0.000107	CbGpPWpGaD
Dipyridamole—ABCC4—Hemostasis—HRAS—urinary bladder cancer	1.15e-05	0.000106	CbGpPWpGaD
Dipyridamole—PDE1A—Disease—SRC—urinary bladder cancer	1.14e-05	0.000106	CbGpPWpGaD
Dipyridamole—ABCC5—Disease—SRC—urinary bladder cancer	1.14e-05	0.000106	CbGpPWpGaD
Dipyridamole—PDE11A—Signaling Pathways—HRAS—urinary bladder cancer	1.13e-05	0.000105	CbGpPWpGaD
Dipyridamole—PDE7A—Signaling Pathways—HRAS—urinary bladder cancer	1.13e-05	0.000105	CbGpPWpGaD
Dipyridamole—PDE1B—Immune System—SRC—urinary bladder cancer	1.13e-05	0.000105	CbGpPWpGaD
Dipyridamole—PDE1B—Disease—CDKN1A—urinary bladder cancer	1.12e-05	0.000104	CbGpPWpGaD
Dipyridamole—PDE1B—Disease—PTEN—urinary bladder cancer	1.12e-05	0.000104	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling by GPCR—KRAS—urinary bladder cancer	1.12e-05	0.000104	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—CXCL8—urinary bladder cancer	1.12e-05	0.000104	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling by GPCR—HRAS—urinary bladder cancer	1.11e-05	0.000103	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—ERBB2—urinary bladder cancer	1.1e-05	0.000102	CbGpPWpGaD
Dipyridamole—PDE1C—Signaling Pathways—TP53—urinary bladder cancer	1.1e-05	0.000102	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—CREBBP—urinary bladder cancer	1.1e-05	0.000102	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—RHOA—urinary bladder cancer	1.09e-05	0.000101	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—IGF1—urinary bladder cancer	1.09e-05	0.000101	CbGpPWpGaD
Dipyridamole—PDE6G—Signaling Pathways—TP53—urinary bladder cancer	1.09e-05	0.000101	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling by GPCR—EGFR—urinary bladder cancer	1.08e-05	0.0001	CbGpPWpGaD
Dipyridamole—PDE1A—Immune System—EGFR—urinary bladder cancer	1.08e-05	0.0001	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—ERBB2—urinary bladder cancer	1.07e-05	9.94e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Disease—EP300—urinary bladder cancer	1.07e-05	9.93e-05	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—IL2—urinary bladder cancer	1.07e-05	9.89e-05	CbGpPWpGaD
Dipyridamole—PDE10A—Signaling Pathways—TP53—urinary bladder cancer	1.06e-05	9.82e-05	CbGpPWpGaD
Dipyridamole—PDE1C—Signaling Pathways—HRAS—urinary bladder cancer	1.05e-05	9.77e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—CXCL8—urinary bladder cancer	1.04e-05	9.69e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Disease—SRC—urinary bladder cancer	1.04e-05	9.66e-05	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—CCND1—urinary bladder cancer	1.04e-05	9.65e-05	CbGpPWpGaD
Dipyridamole—PDE6G—Signaling Pathways—HRAS—urinary bladder cancer	1.04e-05	9.64e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling by GPCR—HRAS—urinary bladder cancer	1.04e-05	9.63e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—urinary bladder cancer	1.04e-05	9.62e-05	CbGpPWpGaD
Dipyridamole—ABCC5—Metabolism—PTEN—urinary bladder cancer	1.03e-05	9.53e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling by GPCR—KRAS—urinary bladder cancer	1.02e-05	9.48e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Immune System—KRAS—urinary bladder cancer	1.02e-05	9.47e-05	CbGpPWpGaD
Dipyridamole—ABCC5—Disease—MYC—urinary bladder cancer	1.02e-05	9.46e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Disease—MYC—urinary bladder cancer	1.02e-05	9.46e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—CXCL8—urinary bladder cancer	1.02e-05	9.43e-05	CbGpPWpGaD
Dipyridamole—PDE10A—Signaling Pathways—HRAS—urinary bladder cancer	1.01e-05	9.39e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling by GPCR—HRAS—urinary bladder cancer	1.01e-05	9.37e-05	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—MMP9—urinary bladder cancer	1.01e-05	9.36e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—ERBB2—urinary bladder cancer	1.01e-05	9.35e-05	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—CDKN1A—urinary bladder cancer	1.01e-05	9.33e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—RRM2—urinary bladder cancer	1e-05	9.31e-05	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—PTEN—urinary bladder cancer	1e-05	9.31e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—IL2—urinary bladder cancer	9.98e-06	9.26e-05	CbGpPWpGaD
Dipyridamole—ABCC5—Disease—EGFR—urinary bladder cancer	9.97e-06	9.25e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Disease—EGFR—urinary bladder cancer	9.97e-06	9.25e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—RHOA—urinary bladder cancer	9.95e-06	9.24e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Immune System—EGFR—urinary bladder cancer	9.88e-06	9.17e-05	CbGpPWpGaD
Dipyridamole—ABCC5—Metabolism—EP300—urinary bladder cancer	9.8e-06	9.09e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—CCND1—urinary bladder cancer	9.73e-06	9.03e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—IL2—urinary bladder cancer	9.71e-06	9.01e-05	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—EP300—urinary bladder cancer	9.56e-06	8.88e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—CXCL8—urinary bladder cancer	9.55e-06	8.87e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling by GPCR—HRAS—urinary bladder cancer	9.49e-06	8.81e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—CCND1—urinary bladder cancer	9.46e-06	8.79e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—MMP9—urinary bladder cancer	9.45e-06	8.77e-05	CbGpPWpGaD
Dipyridamole—ABCC5—Disease—KRAS—urinary bladder cancer	9.42e-06	8.74e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Disease—KRAS—urinary bladder cancer	9.42e-06	8.74e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—CDKN1A—urinary bladder cancer	9.41e-06	8.74e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—PTEN—urinary bladder cancer	9.39e-06	8.72e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Immune System—KRAS—urinary bladder cancer	9.33e-06	8.66e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Disease—MYC—urinary bladder cancer	9.32e-06	8.65e-05	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—SRC—urinary bladder cancer	9.3e-06	8.63e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—HPGDS—urinary bladder cancer	9.29e-06	8.63e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—ENO2—urinary bladder cancer	9.29e-06	8.63e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—ERBB2—urinary bladder cancer	9.21e-06	8.55e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—MMP9—urinary bladder cancer	9.19e-06	8.53e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—CDKN1A—urinary bladder cancer	9.16e-06	8.5e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—PTEN—urinary bladder cancer	9.13e-06	8.48e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—IL2—urinary bladder cancer	9.13e-06	8.47e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Disease—EGFR—urinary bladder cancer	9.12e-06	8.46e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—GSTT1—urinary bladder cancer	9.01e-06	8.37e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—EP300—urinary bladder cancer	8.96e-06	8.31e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—CCND1—urinary bladder cancer	8.9e-06	8.26e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—CXCL8—urinary bladder cancer	8.74e-06	8.11e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—EP300—urinary bladder cancer	8.71e-06	8.09e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—SRC—urinary bladder cancer	8.71e-06	8.08e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling by GPCR—HRAS—urinary bladder cancer	8.68e-06	8.06e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Immune System—HRAS—urinary bladder cancer	8.67e-06	8.05e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—MMP9—urinary bladder cancer	8.64e-06	8.02e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Disease—KRAS—urinary bladder cancer	8.61e-06	8e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—CDKN1A—urinary bladder cancer	8.61e-06	7.99e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—PTEN—urinary bladder cancer	8.59e-06	7.97e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—SRC—urinary bladder cancer	8.47e-06	7.86e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	8.44e-06	7.83e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—IL2—urinary bladder cancer	8.35e-06	7.75e-05	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—MYC—urinary bladder cancer	8.33e-06	7.74e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—EP300—urinary bladder cancer	8.19e-06	7.6e-05	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—EGFR—urinary bladder cancer	8.15e-06	7.57e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—CCND1—urinary bladder cancer	8.14e-06	7.55e-05	CbGpPWpGaD
Dipyridamole—ABCC5—Disease—HRAS—urinary bladder cancer	8e-06	7.43e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Disease—HRAS—urinary bladder cancer	8e-06	7.43e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—SRC—urinary bladder cancer	7.96e-06	7.39e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Immune System—HRAS—urinary bladder cancer	7.93e-06	7.36e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—MMP9—urinary bladder cancer	7.9e-06	7.33e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—CDKN1A—urinary bladder cancer	7.87e-06	7.31e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—PTEN—urinary bladder cancer	7.85e-06	7.29e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—MYC—urinary bladder cancer	7.8e-06	7.24e-05	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—KRAS—urinary bladder cancer	7.7e-06	7.15e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—EGFR—urinary bladder cancer	7.63e-06	7.09e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—MYC—urinary bladder cancer	7.59e-06	7.05e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—EP300—urinary bladder cancer	7.49e-06	6.95e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—NQO1—urinary bladder cancer	7.49e-06	6.95e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—EGFR—urinary bladder cancer	7.42e-06	6.89e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Disease—HRAS—urinary bladder cancer	7.32e-06	6.8e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—SRC—urinary bladder cancer	7.28e-06	6.76e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—KRAS—urinary bladder cancer	7.21e-06	6.69e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—MYC—urinary bladder cancer	7.14e-06	6.63e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—KRAS—urinary bladder cancer	7.01e-06	6.51e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—EGFR—urinary bladder cancer	6.98e-06	6.48e-05	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—TP53—urinary bladder cancer	6.84e-06	6.35e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—KRAS—urinary bladder cancer	6.59e-06	6.12e-05	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—HRAS—urinary bladder cancer	6.55e-06	6.08e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—MYC—urinary bladder cancer	6.53e-06	6.06e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—TP53—urinary bladder cancer	6.41e-06	5.95e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—EGFR—urinary bladder cancer	6.38e-06	5.93e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—GSTP1—urinary bladder cancer	6.25e-06	5.8e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—TP53—urinary bladder cancer	6.23e-06	5.79e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—HRAS—urinary bladder cancer	6.13e-06	5.69e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—KRAS—urinary bladder cancer	6.03e-06	5.6e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—HRAS—urinary bladder cancer	5.96e-06	5.53e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—TP53—urinary bladder cancer	5.86e-06	5.44e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—TYMS—urinary bladder cancer	5.81e-06	5.39e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—NCOR1—urinary bladder cancer	5.74e-06	5.33e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—GSTM1—urinary bladder cancer	5.74e-06	5.33e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—HRAS—urinary bladder cancer	5.61e-06	5.2e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—GPX1—urinary bladder cancer	5.5e-06	5.1e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—ERCC2—urinary bladder cancer	5.4e-06	5.01e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—TP53—urinary bladder cancer	5.36e-06	4.98e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—HRAS—urinary bladder cancer	5.13e-06	4.76e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—MTHFR—urinary bladder cancer	5.07e-06	4.71e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—PPARG—urinary bladder cancer	4.11e-06	3.82e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—CREBBP—urinary bladder cancer	3.95e-06	3.67e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—PTGS2—urinary bladder cancer	3.24e-06	3e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—PTEN—urinary bladder cancer	2.82e-06	2.62e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—EP300—urinary bladder cancer	2.69e-06	2.5e-05	CbGpPWpGaD
